Video

ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL

Author(s):

Loretta J. Nastoupil, MDMarc S. Hoffman, MD

Loretta J. Nastoupil, MD, reviews data from the ZUMA-7 trial investigating the use of axicabtagene ciloleucel as a second-line therapy for large b-cell lymphoma.

Related Videos
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Ana Christina Garrido-Castro, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Jean-Marc Classe, MD, PhD, Nantes Université
Bradley McGregor, MD
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Kevin Kalinsky, MD, MS
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Related Content
Sundar Jagannath, MBBS, director, the Center of Excellence for Multiple Myeloma, professor, Medicine, Mount Sinai Tisch Cancer Institute
June 7th 2024

Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Fernando Cotait Maluf, MD
June 7th 2024

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Roger Li, MD
June 6th 2024

High CR Rate in NMIBC Is Maintained by Cretostimogene Grenadenorepvec Plus Pembrolizumab

Ronald C. Chen, MD, MPH, FASCO, FASTRO
June 6th 2024

Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer